Meeting
2022 ASCO Annual Meeting
Assessing the predictive value of ctDNA on relapse in patients with resected stage IB-IIIA NSCLC treated with adjuvant chemotherapy plus concomitant atezolizumab followed by atezolizumab: BTCRC LUN 19-396.
Authors
Fatemeh Ardeshir-Larijani
Indiana University, Melvin and Bren Simon Cancer Center, Indianapolis, IN
Fatemeh Ardeshir-Larijani , Nisha Anjali Mohindra , Anne M. Traynor , Jyoti Malhotra , Elaine Shum , Patrick C. Ma , Nasser H. Hanna
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT04367311
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS8592)
DOI
10.1200/JCO.2022.40.16_suppl.TPS8592
Abstract #
TPS8592
Poster Bd #
217a
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A phase III trial to compare atezolizumab (atezo) vs best supportive care (BSC) following adjuvant chemotherapy in patients (pts) with completely resected NSCLC: IMpower010.
First Author: Heather A. Wakelee
Poster
2020 ASCO Virtual Scientific Program
Nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated efficacy and safety results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455).
First Author: Christian Grohé
Poster
2018 ASCO Annual Meeting
Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.
First Author: Nathaniel R. Evans
Poster
2017 ASCO Annual Meeting
IMpower132: A phase III clinical program—1L atezolizumab plus platinum-based chemotherapy in chemo-naive advanced non-squamous NSCLC.
First Author: Howard Jack West